TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06614335

Intervention type: OTHER
Intervention: After 6 months of observation, there was still a residual inclination of more than 15 prism degrees which needed to be corrected by a second operation
Description: All IE patients enrolled were patients who had undergone corrective surgery for strabismus. Postoperative strabismus with 10 prism degrees of overcorrection or undercorrection is within the normal range. During postoperative follow-up, patients with more than 10 prism degrees of residual esotropia were treated conservally with foot orthoscopy according to their refractive status. After 6 months of observation, there were still more than 15 prism degrees of residual esotropia that needed to be corrected by a second operation. For extropia with overcorrection greater than 10 prism degrees, cross-eye training, negative mirror + prism stimulation and conservative observation and fusion training are given in the early stage, and can not be improved within 6 months, requiring a second surgical correction.

Intervention type: OTHER
Intervention: After 6 months of observation, there was still a residual inclination of more than 15 prism degrees which needed to be corrected by a second operation
Description: All IE patients enrolled were patients who had undergone corrective surgery for strabismus. Postoperative strabismus with 10 prism degrees of overcorrection or undercorrection is within the normal range. During postoperative follow-up, patients with more than 10 prism degrees of residual esotropia were treated conservally with foot orthoscopy according to their refractive status. After 6 months of observation, there were still more than 15 prism degrees of residual esotropia that needed to be corrected by a second operation. For extropia with overcorrection greater than 10 prism degrees, cross-eye training, negative mirror + prism stimulation and conservative observation and fusion training are given in the early stage, and can not be improved within 6 months, requiring a second surgical correction.
Study: NCT06613763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC
Study: NCT06613763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05520619

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
Study: NCT05727579

Intervention type: OTHER
Group type: OTHER
Intervention: Salt-Diet and/or Ertugliflozin
Description: The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Salt-Diet and/or Ertugliflozin
Description: The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Salt-Diet and/or Ertugliflozin
Description: The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Salt-Diet and/or Ertugliflozin
Description: The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT04861051

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Study participants will receive 0.5mg/kg of ketamine - one single infusion
Study: NCT06692985

Intervention type: OTHER
Intervention: Clinical and epidemiological data
Description: Collection of clinical and epidemiological data on day 0

Intervention type: OTHER
Intervention: Parasitological samples
Description: Parasitological samples : smear for on-site analysis and swabs to be sent to the Cayenne Hospital for PCR at day 0

Intervention type: OTHER
Intervention: Assessment of clinical course and response to treatment
Description: Follow-up visit with assessment of clinical course and response to treatment at M6

Intervention type: OTHER
Intervention: DLQI questionnaire
Description: DLQI questionnaire at M6
Study: NCT06691893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RELiZORB
Description: RELiZORB (immobilized lipase) is a therapeutic device designed to enhance fat absorption in patients receiving enteral tube feedings. It works by hydrolyzing fats found in enteral formulas. RELiZORB is a single-use cartridge that connects in-line with enteral feeding sets. It contains lipase covalently bound to small polymer beads, forming a complex called iLipase, which remains within the cartridge. As the enteral formula passes through the cartridge, its fat content is hydrolyzed upon contact with iLipase. This process is especially beneficial for the absorption of long-chain polyunsaturated fatty acids, which require hydrolysis by pancreatic lipase for proper intestinal absorption. RELiZORB is compatible with a wide variety of commercially available enteral formulas.
Study: NCT05513235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital personal health record
Description: The digital personal health record is a mobile application ('app') entitled Caremap. The mobile app will be downloaded and accessible by parents/caregivers to help coordinate care.
Study: NCT06682117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC Vaccine
Description: Patients will receive Neo-DC vaccine infusion either by dose 1 (1×10\^7 cells/time) or dose 2 (5×10\^7 cells/time) every 7 days, four cell infusions are one treatment cycle.~The dose limited toxity observation time is within 28 days after the first Neo-DC vaccine infusion.~If the efficacy is evaluated as clinical benefit (CR/PR/SD) or immune unconfirmed progress ( iUPD), treatment cycle can be continued until the completion of four Neo-DC vaccine administrations or disease progression (iCPD by iRECIST) or start new anti-tumor treatment or stop treatment by other reasons.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT06137755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-VZV-001
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-VZV-001
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-VZV-001
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Investigational Product
Study: NCT06697561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education program
Description: The intervention for the experimental group was an evidence-based educational program for hand dysfunction in patients with systemic sclerosis, which included a health education manual and multimedia videos developed through evidence translation. Additionally, individual education and consultation were provided.
Study: NCT06632262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061 + ABSK043
Description: Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061 + ABSK043
Description: Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061 + ABSK043
Description: Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061+ABSK043 in combination with CAPOX
Description: Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
Study: NCT06696989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frenkel's exercises
Description: In this group, participants will receive Frenkel's exercises, and the total treatment session will be 60 minutes of routine physical therapy, i.e., breathing, stretching, ROM's, and joint mobility, with rest intervals in between for 20 minutes. To begin the intervention, the investigator will perform Frenkel's exercises for 40 minutes in total, with rest intervals between each exercise, initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively, after 2 weeks.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT06696989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises
Description: This group participants will receive core stability exercises, and the total treatment session will also be 60 minutes. The routine physical therapy includes breathing, stretching, joint rotations, ROM's, and frequent periods of rest in between the treatment sessions. To begin the intervention the investigator will perform core stability exercises for 40 minutes in total with rest intervals between each exercise and initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively after 2 weeks.
Study: NCT06696924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reciprocal inhibition
Description: First Subjects will start doing baseline warmup exercises which are mentioned then they will perform reciprocal inhibition of the serratus muscle in supine or side-lying. After identifying the antagonist muscles of the serratus anterior, which are typically the rhomboids or the middle and lower trapezius. Athletes will perform a gentle contraction of the antagonist's muscles by retracting or squeezing their shoulder blades together. While the antagonist muscles are contracting, we will ask the athlete to simultaneously relax and lengthen the serratus anterior muscle. The patient can achieve this by protracting or pushing their shoulder blades forward and away from each other.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Subjects will perform 2 stretches~1. Standing Wall Stretch: Stand facing a wall with your feet about hip-width apart. Place their palms on the wall at shoulder height, slightly wider than shoulder-width apart. will Lean their body forward, keeping their arms straight, until feel a stretch in their serratus anterior. Hold the stretch for 15 to 30 seconds, then slowly release. Instead of using a wall or object, the athlete will use their opposite hand to hold the stretched arm in position.~2. Seated Cross-Body Stretch: Sit on the edge of a chair or bench. Cross one arm over your chest, placing your hand on the opposite shoulder. The athlete will use the other hand to gently pull the crossed arm closer to your body, feeling a stretch in the serratus anterior. Hold the stretch for 15 to 30 seconds or more, and then switch sides and repeat.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT06697067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified smead jones
Description: interrupted suture technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional comtinuous suture techniques
Description: continuous suture technique
Study: NCT06697119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal suspension is delivered to duodenal 3rd portion via esophagogastroduodenoscopy
Study: NCT06696950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutimodal gait training includes unilateral step training, inclined treadmill training, over ground training with rhythmic auditory stimulation
Description: Unilateral step training, inclined treadmill training, over ground training, repetitive isochronous pulses via metronome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal gait training
Description: Unilateral step training, inclined treadmill training, over ground training,
Study: NCT06696872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core exercises
Description: The core muscle strength training program were lasted for 8 weeks and comprised of 3 training sessions per week, with a total of 24 sessions. Each session were lasted for 30 to 45 minutes, starting with a brief warm-up exercise program consisting of low-intensity core strength exercises to prepare the neuromuscular system for the training loads and ending with a cool-down program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: The hold-relax proprioceptive neuromuscular facilitation stretching protocol consisted of passively moving the dominant leg into a position where the subjects felt mild discomfort and holding that position for 30 seconds. Subjects were then asked to isometrically contract the stretched muscle for 10 seconds; this were followed by muscle relaxation in the same posi¬tion for 30 seconds, before being stretched to a new point of mild discomfort. The leg were then released
Study: NCT06484764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-fluoroscopy guided robot-assisted biopsy of thoracic and abdominal lesions
Description: During the procedure, the participant first undergoes a CT scan the radiologist plans the needle trajectory based on the registered preoperative CECT (contrast-enhanced computed tomography~) and intraoperative CT. After the participant is manually sterilised and given local anaesthesia, the radiologist will remotely control the robot to finish the needle insertion process under the CT-fluoroscopy guidance and simultaneously adjust the angular needle if necessary. The radiologist confirms whether the needle has reached the target area by CT-fluoroscopy image.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions
Description: Radiologists following the current clinical practice guidance to finish the freehand biopsy procedure under the CT guidance.
Study: NCT05764603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI
Description: MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
Study: NCT05386719

Intervention type: OTHER
Group type: OTHER
Intervention: Prescreening
Description: Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status \& questions about cardiovascular disease.

Intervention type: OTHER
Group type: OTHER
Intervention: Screening and Enrollment
Description: Consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Baseline
Description: Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpret BMI
Description: Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Interpret HbA1c
Description: HbA1c results categorized as follows:~HbA1c \<5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication

Intervention type: OTHER
Group type: OTHER
Intervention: Interpret lipid panel and assess other risk factors
Description: Based on above categories:~HbA1c \<5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol \>200, family history of Coronary Artery Disease/Heart Attack in first degree family \<55 year old male or \<65 year old female, systolic blood pressure \>130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assess 10 year risk of cardiovascular event
Description: If risk factors are present - refer to Cardiovascular Disease Prevention Program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recommendations
Description: Provide individual patient handout based on all above interventions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Follow-Up
Description: 6 and 12 month labs (if prior abnormal) and Patient Reported Outcome questionnaires
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT05881785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1501 low dose
Description: 3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1501 high dose
Description: 3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Core treatment period:placebo~* Maintenance treatment period: GR1501 injection
Study: NCT06003101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC)
Description: Bone marrow aspiration from the body of the ilium will be performed through one of the arthroscopic portals.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of care hip arthroscopy without bone marrow aspiration will be performed in these patients.
Study: NCT04912206

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasound
Description: Abdominal clinician-performed Ultrasound